{"id":761429,"date":"2023-06-02T17:09:21","date_gmt":"2023-06-02T21:09:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/"},"modified":"2023-06-02T17:09:21","modified_gmt":"2023-06-02T21:09:21","slug":"rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/","title":{"rendered":"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)"},"content":{"rendered":"

<\/p>\n

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)<\/b><\/p>\n

DUBLIN–(BUSINESS WIRE<\/a>)–
\nHorizon Therapeutics plc (NASDAQ: HZNP):<\/p>\n

IRISH TAKEOVER PANEL<\/b><\/p>\n

DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022<\/b><\/p>\n

BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS<\/b><\/p>\n

1. KEY INFORMATION<\/b><\/p>\n\n\n\n\n\n\n\n
\n

(a) Full name of discloser:<\/b><\/p>\n<\/td>\n

\n

\nElizabeth Crossan<\/p>\n<\/td>\n<\/tr>\n

\n

(b) Owner or controller of interests and short<\/b>positions disclosed, if different from 1(a):<\/b><\/p>\n

\n\u00a0<\/p>\n

The naming of nominee or vehicle companies is<\/i>insufficient. For a trust, the trustee(s), settlor and<\/i>beneficiaries must be named.<\/i><\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n<\/tr>\n

\n

(c) Name of offeror\/offeree in relation to whose<\/b>relevant securities this form relates:<\/b><\/p>\n

\n\u00a0<\/p>\n

Use a separate form for each offeror\/offeree<\/i><\/p>\n<\/td>\n

\n

\nHorizon Therapeutics plc<\/p>\n<\/td>\n<\/tr>\n

\n

(d) Status of person making the disclosure:<\/b><\/p>\n

\n\u00a0<\/p>\n

e.g. offeror, offeree, person acting in concert with the<\/i>offeror\/offeree (specify name of offeror\/offeree)<\/i><\/p>\n<\/td>\n

\n

\nPerson acting in concert with the offeree (namely, a sibling of a director of the offeree)<\/p>\n<\/td>\n<\/tr>\n

\n

(e) Date dealing undertaken:<\/b><\/p>\n<\/td>\n

\n

\nJune 1, 2023<\/p>\n<\/td>\n<\/tr>\n

\n

(f) In addition to the company in 1(c) above, is the<\/b>discloser also making disclosures in respect of<\/b>any other party to the offer?<\/b><\/p>\n

\n\u00a0<\/p>\n

If it is a cash offer or possible cash offer, state \u201cN\/A\u201d<\/i><\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

2. INTERESTS AND SHORT POSITIONS<\/b><\/p>\n

If there are positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.<\/i><\/p>\n

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing <\/b>(Note 1)<\/p>\n\n\n\n\n\n\n\n\n
\n

Class of relevant security:
\n
<\/b>(Note 2)<\/p>\n<\/td>\n

\n

\nOrdinary shares of US$0.0001 each (“Ordinary Shares<\/b>“)<\/p>\n<\/td>\n<\/tr>\n

\n\n

Interests<\/b><\/p>\n<\/td>\n

\n

Short positions<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

Number<\/b><\/p>\n<\/td>\n

\n

%<\/b><\/p>\n<\/td>\n

\n

Number<\/b><\/p>\n<\/td>\n

\n

%<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

(1) Relevant securities owned<\/b>and\/or controlled:<\/b><\/p>\n<\/td>\n

\n

\n13,745<\/p>\n<\/td>\n

\n

\n0.006%<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n<\/tr>\n

\n

(2) Cash-settled derivatives:<\/b><\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n<\/tr>\n

\n

(3) Stock-settled derivatives<\/b>(including options) and<\/b>agreements to purchase\/sell:<\/b><\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n<\/tr>\n

\n

Total:<\/b><\/p>\n<\/td>\n

\n

\n13,745<\/p>\n<\/td>\n

\n

\n0.006%<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n* The Rule 8.1 Disclosure released 16 March 2023 incorrectly stated the number of relevant securities owned and\/or controlled by Elizabeth Crossan as 13,191. The number of relevant securities owned and\/or controlled by Elizabeth Crossan on 15 March 2023 was 13,571.<\/p>\n

All interests and all short positions should be disclosed.<\/i><\/p>\n

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 .<\/i><\/p>\n

3. DEALINGS BY THE PERSON MAKING THE DISCLOSURE <\/b>(Note 3)<\/p>\n

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.<\/i><\/p>\n

The currency of all prices and other monetary amounts should be stated.<\/i><\/p>\n

(a) Purchases and sales<\/b><\/p>\n

(i) Offeree, offeror or person acting in concert (except for a principal trader in the same group as a financial or other professional adviser acting in relation to the offer for the offeree or the offeror)<\/b><\/p>\n\n\n\n
\n

Class of
\n
relevant
\n
security<\/b><\/p>\n<\/td>\n

\n

Purchase\/sale<\/b><\/p>\n<\/td>\n

\n

Number of
\n
securities<\/b><\/p>\n<\/td>\n

\n

Price per unit
\n
<\/b>(Note 4)<\/p>\n<\/td>\n<\/tr>\n

\n

\nOrdinary Shares<\/p>\n<\/td>\n

\n

\nPurchase<\/p>\n<\/td>\n

\n

\n174<\/p>\n<\/td>\n

\n

\n$76.07<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

(ii) Principal trader where the sole reason for the connection is that the principal trader is in the same group as a financial or other professional adviser acting in relation to the offer for the offeree or the offeror<\/b><\/p>\n\n\n\n
\n

Class of
\n
relevant
\n
security<\/b><\/p>\n<\/td>\n

\n

Purchases\/
\n
sales<\/b><\/p>\n<\/td>\n

\n

Total
\n
number of
\n
securities<\/b><\/p>\n<\/td>\n

\n

Highest
\n
price per
\n
unit paid\/
\n
received<\/b><\/p>\n<\/td>\n

\n

Lowest
\n
price per
\n
unit paid\/
\n
received<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

(b) Cash-settled derivative transactions<\/b><\/p>\n\n\n\n
\n

Class of
\n
relevant
\n
security<\/b><\/p>\n<\/td>\n

\n

Product
\n
description
\n
<\/b>e.g. CFD<\/i><\/p>\n<\/td>\n

\n

Nature of
\n
dealing
\n
<\/b>e.g. opening\/
\n<\/i>
closing a long\/
\n
short position,
\n
increasing\/
\n
reducing a long\/
\n<\/i>
short position<\/i><\/p>\n<\/td>\n

\n

Number of
\n
reference
\n
securities
\n
<\/b>(Note 5)<\/p>\n<\/td>\n

\n

Price
\n
per unit
\n
<\/b>(Note 4)<\/p>\n<\/td>\n<\/tr>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

(c) Stock-settled derivative transactions (including options)<\/b><\/p>\n

(i) Writing, selling, purchasing or varying<\/b><\/p>\n\n\n\n
\n

Class of
\n<\/b>
relevant
\n<\/b>
security<\/b><\/p>\n<\/td>\n

\n

Product
\n<\/b>
description
\n<\/b>
e.g. call
\n<\/i>
option<\/i><\/p>\n<\/td>\n

\n

Writing,
\n
purchasing,
\n<\/b>
selling,
\n<\/b>
varying etc.<\/b><\/p>\n<\/td>\n

\n

Number
\n
of
\n<\/b>
securities
\n<\/b>
to which
\n<\/b>
option
\n<\/b>
relates
\n<\/b>
(Note 5)<\/p>\n<\/td>\n

\n

Exercise
\n<\/b>
price per
\n<\/b>
<\/i>unit<\/b><\/p>\n<\/td>\n

\n

Type
\n
<\/b>e.g.
\n<\/i>
American,
\n<\/i>
European
\n<\/i>
etc.<\/i><\/p>\n<\/td>\n

\n

Expiry
\n<\/b>
date<\/b><\/p>\n<\/td>\n

\n

Option
\n<\/b>
money
\n<\/b>
paid\/
\n<\/b>
received
\n<\/b>
per unit<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

(ii) Exercise<\/b><\/p>\n\n\n\n
\n

Class of
\n<\/b>
relevant
\n<\/b>
security<\/b><\/p>\n<\/td>\n

\n

Product
\n<\/b>
description
\n<\/b>
e.g. call
\n<\/i>
option<\/i><\/p>\n<\/td>\n

\n

Exercising\/
\n<\/b>
exercised
\n<\/b>
against<\/b><\/p>\n<\/td>\n

\n

Number of
\n<\/b>
securities<\/b><\/p>\n<\/td>\n

\n

Exercise
\n<\/b>
price
\n<\/b>
per unit
\n<\/b>
(Note 4)<\/p>\n<\/td>\n<\/tr>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

(d) Other dealings (including transactions in respect of new securities)<\/b><\/p>\n\n\n\n
\n

Class of
\n<\/b>
relevant
\n<\/b>
security<\/b><\/p>\n<\/td>\n

\n

Nature of dealing
\n<\/b>
e.g. subscription,
\n<\/i>
conversion, exercise<\/i><\/p>\n<\/td>\n

\n

Details<\/b><\/p>\n<\/td>\n

\n

Price per unit
\n<\/b>
(if applicable)
\n<\/b>
(Note 4)<\/p>\n<\/td>\n<\/tr>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n

\n

\nN\/A<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

4. OTHER INFORMATION<\/b><\/p>\n

(a) Indemnity and other dealing arrangements<\/b><\/p>\n\n\n\n
\n

Details of any indemnity or option arrangement, or any agreement<\/b>or understanding, formal or informal, relating to relevant securities<\/b>which may be an inducement to deal or refrain from dealing<\/b>entered into by the party to the offer or person acting in concert<\/b>making the disclosure and any other person:<\/b><\/p>\n

\n\u00a0<\/p>\n

Irrevocable commitments and letters of intent should not be included. If<\/i>there are no such agreements, arrangements or understandings, state<\/i>\u201cnone\u201d<\/i><\/p>\n<\/td>\n<\/tr>\n

\n

\nN\/A<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

(b) Agreements, arrangements or understandings relating to options or derivatives<\/b><\/p>\n\n\n\n
\n

Full details of any agreement, arrangement or understanding<\/b>between the person disclosing and any other person relating to the<\/b>voting rights of any relevant securities under any option referred to<\/b>on this form or relating to the voting rights or future acquisition or<\/b>disposal of any relevant securities to which any derivative referred<\/b>to on this form is referenced. If none, this should be stated.<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nN\/A<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

(c) Attachments<\/b><\/p>\n\n\n\n
\n

Is a Supplemental Form 8 attached?<\/b><\/p>\n<\/td>\n

\n

YES\/NO<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nNo<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n\n\n
\n

Date of disclosure:<\/b><\/p>\n<\/td>\n

\n

\nJune 2, 2023<\/p>\n<\/td>\n<\/tr>\n

\n

Contact name:<\/b><\/p>\n<\/td>\n

\n

\nAidan Milstead<\/p>\n<\/td>\n<\/tr>\n

\n

Telephone number:<\/b><\/p>\n<\/td>\n

\n

\n+1 224 206 4983<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

Public disclosures under Rule 8.1 of the Rules must be made to a Regulatory Information Service.<\/i><\/p>\n

NOTES ON FORM 8.1(c) and (d)(i)<\/b><\/p>\n

1. See the definition of \u201cinterest in a relevant security\u201d in Rule 2.5 of Part A of the Rules and see Rule 8.6(b) of Part B of the Rules.<\/i><\/b><\/p>\n

2. See the definition of \u201crelevant securities\u201d in Rule 2.1 of Part A of the Rules.<\/i><\/b><\/p>\n

3. See the definition of \u201cdealing\u201d in Rule 2.1 of Part A of the Rules.<\/i><\/b><\/p>\n

4. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.<\/i><\/b><\/p>\n

5. See Rule 2.5(d) of Part A of the Rules.<\/i><\/b><\/p>\n

6. If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.<\/i><\/b><\/p>\n

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.<\/i><\/b><\/p>\n

References in these notes to \u201cthe Rules\u201d are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.<\/i><\/b><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230602005237\/en\/<\/a><\/span><\/p>\n

\nAidan Milstead 1 (224) 206 4983<\/p>\n

KEYWORDS:<\/b> Ireland Europe<\/p>\n

INDUSTRY KEYWORDS:<\/b> General Health Professional Services Health Finance<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) DUBLIN–(BUSINESS WIRE)– Horizon Therapeutics plc (NASDAQ: HZNP): IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS 1. KEY INFORMATION (a) Full name of discloser: Elizabeth Crossan (b) Owner or controller of interests and shortpositions disclosed, if different from 1(a): \u00a0 The naming of nominee or vehicle companies isinsufficient. For a trust, the trustee(s), settlor andbeneficiaries must be named. N\/A (c) Name of offeror\/offeree in relation to whoserelevant securities this form relates: \u00a0 Use a separate form for each offeror\/offeree Horizon Therapeutics … <\/p>\n

Continue reading “Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-761429","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRule 8.1 Dealing Disclosure (Horizon Therapeutics plc) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) DUBLIN–(BUSINESS WIRE)– Horizon Therapeutics plc (NASDAQ: HZNP): IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS 1. KEY INFORMATION (a) Full name of discloser: Elizabeth Crossan (b) Owner or controller of interests and shortpositions disclosed, if different from 1(a): \u00a0 The naming of nominee or vehicle companies isinsufficient. For a trust, the trustee(s), settlor andbeneficiaries must be named. N\/A (c) Name of offeror\/offeree in relation to whoserelevant securities this form relates: \u00a0 Use a separate form for each offeror\/offeree Horizon Therapeutics … Continue reading "Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-02T21:09:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230602005237r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)\",\"datePublished\":\"2023-06-02T21:09:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\\\/\"},\"wordCount\":1205,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230602005237r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\\\/\",\"name\":\"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230602005237r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-06-02T21:09:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230602005237r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230602005237r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/","og_locale":"en_US","og_type":"article","og_title":"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) - Market Newsdesk","og_description":"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) DUBLIN–(BUSINESS WIRE)– Horizon Therapeutics plc (NASDAQ: HZNP): IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS 1. KEY INFORMATION (a) Full name of discloser: Elizabeth Crossan (b) Owner or controller of interests and shortpositions disclosed, if different from 1(a): \u00a0 The naming of nominee or vehicle companies isinsufficient. For a trust, the trustee(s), settlor andbeneficiaries must be named. N\/A (c) Name of offeror\/offeree in relation to whoserelevant securities this form relates: \u00a0 Use a separate form for each offeror\/offeree Horizon Therapeutics … Continue reading \"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-02T21:09:21+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230602005237r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)","datePublished":"2023-06-02T21:09:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/"},"wordCount":1205,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230602005237r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/","name":"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230602005237r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-06-02T21:09:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230602005237r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230602005237r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rule-8-1-dealing-disclosure-horizon-therapeutics-plc-20\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/761429","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=761429"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/761429\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=761429"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=761429"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=761429"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}